GlassScriptPhysician profile
Francisco Tamayo
NPI 1982691804
$2,881.87
in general payments reported to CMS, 2019-2025
16 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2023: $1,479 · 2024: $1,033 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513 · Travel and Lodging: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.75 |
| Travel and Lodging | $1,112.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,183.57 | 2023-2024 | Single Use Suction Valve (Sterile), Olympus, Vizishot 2 Flex |
| Astrazeneca Pharmaceuticals LP | $334.72 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $310.51 | 2023-2024 | |
| Glaxosmithkline, LLC. | $289.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| United Therapeutics Corporation | $162.96 | 2023-2024 | Tyvaso |
| Janssen Pharmaceuticals, INC | $109.25 | 2019 | |
| Mylan Specialty L.P. | $101.29 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.00 | 2019-2023 | Ofev |
| Actelion Pharmaceuticals US, INC. | $63.42 | 2024 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $53.50 | 2024 | Glassia |
| Merck Sharp & Dohme LLC | $47.07 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Amgen INC. | $44.47 | 2023 | Tezspire |
| Stryker Corporation | $26.26 | 2025 | Flowtriever |
| Novartis Pharmaceuticals Corporation | $24.02 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.91 | 2024 | Lifevest |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $21.19 | 2023 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Tamayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.